Literature DB >> 22053304

Vogt-Koyanagi-Harada disease in an 8-year-old boy.

Budi Setiabudiawan1, Feti Karfiati, Reni Ghrahani, Gartika Sapartini, Indra Sahril.   

Abstract

Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disease involving pigmented tissue in eyes, auditory system, skin, and central nervous system. The pathogenesis is a result of T cell lymphocyte reaction against melanocyte component, tyrosinase and tyrosinase-related protein. This disease uniquely affected pigmented race in Asia and native America, mostly women aged 20-50. We reported an 8-years-old boy complained for visual disturbance since 6 weeks prior admission. Two years earlier, the parents noted the patient eyes were looked red when photographed (suggesting a dilated pupil) preceded by whitened on the right forehead and nose and whitened hair, eyebrow and eyelashes. The examination showed a vitiligo and skin atrophy on right frontal and right nasal, poliosis on the eyebrows, eyelids and hair. The diameter of right pupil was 8 mm, with a paresis on 3rd, 4th, 6th, and 9th nerves. Fundus examination revealed sunset glow appearance. The visual acuity on the right eye: 2/60, left eye: 1-0. There's positive serology for antitoxoplasma IgG, anti Rubella IgG, anti CMV IgG. The patient was diagnosed with a VKH disease and then prescribed with methylprednisolone 1 mg/kg/day. The patient also had further follow up with dermatovenerologist and ophthalmologist. The eye examination revealed an improvement on right eye panuveitis, with a remaining keratic precipitate in the endothelium, and minimal flare and cell on the anterior chamber. ENT consultation revealed no ear inflammation or hearing disturbance.

Entities:  

Keywords:  Melanocyte; Methylprednisolone; Visual disturbance; Vogt-Koyanagi-Harada

Year:  2011        PMID: 22053304      PMCID: PMC3206249          DOI: 10.5415/apallergy.2011.1.2.98

Source DB:  PubMed          Journal:  Asia Pac Allergy        ISSN: 2233-8276


  15 in total

1.  Inflammatory vitiligo in Vogt-Koyanagi-Harada disease.

Authors:  D Tsuruta; T Hamada; H Teramae; H Mito; M Ishii
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

Review 2.  Vogt-Koyanagi-Harada disease.

Authors:  Russell W Read
Journal:  Ophthalmol Clin North Am       Date:  2002-09

3.  Anti-SS-A/Ro reactivity in patients with Vogt-Koyanagi-Harada syndrome.

Authors:  M Shinzato; J H Yamamoto; C E Hirata; E Olivalves; E Bonfá
Journal:  Lupus       Date:  2004       Impact factor: 2.911

4.  Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease.

Authors:  K Gocho; I Kondo; K Yamaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-08       Impact factor: 4.799

5.  Early manifestation of vogt-koyanagi-harada disease as unilateral posterior scleritis.

Authors:  Noriko Kouda; Hiroshi Sasaki; Sachiko Harada; Yoshihisa Yamada; Nobuo Takahashi; Kazuyuki Sasaki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

6.  Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.

Authors:  P E Rubsamen; J D Gass
Journal:  Arch Ophthalmol       Date:  1991-05

7.  Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.

Authors:  Peizeng Yang; Yalin Ren; Bing Li; Wang Fang; Qianli Meng; Aize Kijlstra
Journal:  Ophthalmology       Date:  2006-11-21       Impact factor: 12.079

8.  Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories.

Authors:  Felipe Theodoro Bezerra Gaspar Carvalho da Silva; Francisco Max Damico; Maria Lucia Marin; Anna Carla Goldberg; Carlos Eduardo Hirata; Pedro Henrique Takiuti; Edilberto Olivalves; Joyce Hisae Yamamoto
Journal:  Am J Ophthalmol       Date:  2008-11-07       Impact factor: 5.258

9.  Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.

Authors:  Soon-Phaik Chee; Aliza Jap; Kristine Bacsal
Journal:  Am J Ophthalmol       Date:  2008-10-02       Impact factor: 5.258

10.  Significant prognostic factors for Vogt-Koyanagi-Harada disease in the early stage.

Authors:  Shwu-Jiuan Sheu; Hsi-Kung Kou; Jane-Fang Chen
Journal:  Kaohsiung J Med Sci       Date:  2004-03       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.